Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
A more personalised approach to hepatitis C treatment may improve adherence and completion rates

People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as

Published
11 February 2015
By
Roger Pebody
CROI 2015 Preview: New Research on HIV, Hepatitis C and Ebola

It's the beginning of the year, which means another Conference on Retroviruses and Opportunistic Infections (CROI) is upon us. This year's CROI takes place in Seattle and should prove to be another exciting conference as new research is presented.

Published
11 February 2015
From
The Body Pro
Gilead faces challenge to European patent on pricey hep C drug

Global health charity Medecins du Monde (MdM) launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of charging "exorbitant" prices for a hepatitis C drug.

Published
10 February 2015
From
Reuters
Promising data bodes well for all-Achillion hep C treatment

Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.

Published
10 February 2015
From
Reuters
Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

Achillion Pharmaceuticals, Inc. today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.

Published
09 February 2015
From
Achillion press release
Worldwide treatment of hepatitis C could be within sight at the right cost

Lowering the cost of hepatitis C drugs is possible and it is key to achieving global access to treatment, according to new research.

Published
09 February 2015
From
Imperial College press release
Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB

President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for CDC's viral hepatitis and HIV prevention efforts, boost spending for HIV research, and allocate more to combat antibiotic resistance. But the plan would cut overall global health funding, including support for the Global Fund to Fight AIDS, Malaria, and Tuberculosis.

Published
09 February 2015
From
HIVandHepatitis.com
Portugal agrees to treat 13,000 hepatitis C patients

The Portuguese government has agreed to treat up to 13,000 people infected with hepatitis C in the next three years, Portuguese Minister of Health Paulo Macedo said on Friday.

Published
09 February 2015
From
Xinhua
What the 'Shocking' Gilead Discounts on its Hepatitis C Drugs Will Mean

Discounts for the treatments, which Gilead and its supporters argue are more cost-effective than the previous standard of care, will more than double this year – to 46%, on average. Gilead cited the need to offer lower prices to Medicaid and the U.S. Department of Veterans Affairs, in particular.

Published
05 February 2015
From
Wall Street Journal (blog)
Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion

But sales of Sovaldi were lower than they might have been because of Gilead’s introduction of an even newer hepatitis C drug, Harvoni, which recorded $2.1 billion in sales since its approval in October. Together Sovaldi and Harvoni achieved $12.4 billion in sales, just short of Humira’s total.

Published
05 February 2015
From
New York Times

Filter by country